TKNO Alpha Teknova, Inc. logo

TKNO Alpha Teknova, Inc.

Healthcare
$3.89+0.52%ClosedMarket Cap: $208.6M

As of 2026-05-25

Valuation

View Details

P/E (TTM)

PEG

P/B

3.21

P/S

4.99

EV/EBITDA

-21.95

DCF Value

$-11.61

FCF Yield

-4.3%

Div Yield

0.0%

Margins & Returns

Gross Margin

33.3%

Operating Margin

-39.0%

Net Margin

-41.1%

ROE

-24.3%

ROA

-17.4%

ROIC

-17.4%

Financials

View All
PeriodRevenueNet IncomeEPS
Q1 null$11.1M$-4.6M$
Q4 null$10.0M$-4.8M$
FY null$40.5M$-17.3M$
Q3 null$10.5M$-4.3M$

Analyst Ratings

View All

Consensus

Buy

Target (Consensus)

$—

Target (Median)

$—

Target Range

$— - $—

0 Strong Buy4 Buy2 Hold0 Sell0 Strong Sell

Trading Activity

Insider Trades

View All
Terrill Damonofficer: General Counsel and CCO
SellMon Mar 09
Lowell Matthewofficer: Chief Financial Officer
BuyMon Mar 09
Lowell Matthewofficer: Chief Financial Officer
SellMon Mar 09
Gunstream Stephendirector, officer: President and CEO
BuyMon Mar 09
Gunstream Stephendirector, officer: President and CEO
SellMon Mar 09

Company Info

Sector

Healthcare

Industry

Drug Manufacturers - Specialty & Generic

Country

US

Exchange

Beta

0.47

Alpha Teknova, Inc. provides critical reagents for life sciences market in the United States and internationally. Its reagents enable the discovery, development, and production of biopharmaceutical products, such as drug therapies, novel vaccines, and molecular diagnostics. The company offers pre-poured media plates for cell growth and cloning; liquid cell culture media and supplements for cellular expansion; and molecular biology reagents for sample manipulation, resuspension, and purification. It serves life sciences market, including pharmaceutical and biotechnology companies, contract development and manufacturing organizations, in vitro diagnostic franchises, and academic and government research institutions. The company was founded in 1996 and is headquartered in Hollister, California.

Peers